Conference Coverage
Conference Coverage
Eat more dairy, less red meat to prevent type 2 diabetes
Not all animal foods are alike when it comes to their association with type 2 diabetes risk, shows a large new review. The devil is in the details...
Conference Coverage
Whole grains may improve survival in people with type 2 diabetes
Fish, whole grain, fiber, and polyunsaturated fats are found to reduce premature death in a large overview of studies in people with type 2...
Conference Coverage
Waist-hip ratio beats BMI for predicting obesity’s mortality risk
Data from more than 380,000 people in the UK Biobank show waist-to-hip ratio estimated mortality risk from obesity better than BMI or fat mass...
Conference Coverage
‘Game changer’ semaglutide halves diabetes risk from obesity
Post-hoc analysis of two semaglutide trials in people with obesity showed treatment cut their projected 10-year risk for incident type 2 diabetes...
Conference Coverage
Experts express caution over
type 2 diabetes/tea-drinking claim
Drinking four cups of tea a day was linked to a 17% lower risk for developing type 2 diabetes in a study, but experts warn these data are...
Conference Coverage
At EASD, docs to eye new tactics for type 2 diabetes
New data on tirzepatide for weight loss and potential type 2 diabetes remission as well as an update on use of dapagliflozin for heart failure...
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
Conference Coverage
Albuminuria linked to higher CVD risk in diabetes
An analysis of more than 74,000 Danish people with type 2 diabetes showed an elevated CVD event rate in those with albuminuria.
Conference Coverage
DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening
Comprehensive cardiovascular screening fell short of significantly reducing all-cause mortality in men aged 65-74, but some benefits were seen.
Conference Coverage
Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER
Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction–agnostic...